Hormonal
Insulin is the primary regulator of human adipose tissue lipoprotein lipase (LPL) activity; insulin deficiency (as in untreated diabetes) significantly reduces LPL activity, while elevated insulin levels (as in obesity or post-prandial states) increase it.
Your body's ability to store fat in adipose tissue is directly controlled by insulin. When you are insulin-deficient (untreated diabetes), fat storage capacity (LPL) is low. When you have high insulin (obesity or after eating carbs), fat storage capacity increases. Managing insulin secretion through dietary carbohydrate intake is the lever to control this enzyme's activity.
Thus, insulin appears to be important in the regulation of human adipose tissue lipoprotein lipase activity. Elevated insulin levels in obesity and increased insulin secretion after eating were associated with increased lipoprotein lipase activity. Defects in insulin secretion... are associated with low adipose tissue lipoprotein lipase and may lead to hypertriglyceridemia in diabetic man.
Why this rating
Direct measurement of tissue enzyme activity in humans with clear statistical significance (P<0.001) for key findings.
Source
Determinants of human adipose tissue lipoprotein lipase. Effect of diabetes and obesity on basal- and diet-induced activity.
Olavi Pykälistö et al. · Journal of Clinical Investigation · 1975
DOI 10.1172/jci108185
More from this paper
- Dietary carbohydrate intake drives post-prandial increases in adipose tissue lipoprotein lipase (LPL) activity via insulin secretion; high-carbohydrate, fat-free diets significantly increase LPL, whereas fat-containing diets do not.Good
- Untreated diabetic patients fail to increase adipose tissue lipoprotein lipase (LPL) activity in response to high-carbohydrate feeding due to defective insulin secretion, whereas control subjects show marked increases.Good
Related findings · Hormonal
- Initial treatment for type 2 diabetes should be a combination of metformin and either an SGLT-2 inhibitor or a GLP-1 receptor agonist to achieve cardiorenal protection, rather than monotherapy or older agents like sulfonylureas.Strong
- For patients with specific monogenic obesity syndromes (leptin deficiency, POMC/PCSK1/LEPR mutations), targeted pharmacotherapy (recombinant leptin or setmelanotide) is highly effective and should be prioritized, unlike in polygenic obesity.Strong
- Continued weekly administration of 2.4 mg subcutaneous semaglutide prevents weight regain and promotes further weight loss in adults with overweight or obesity, whereas switching to placebo results in significant weight regain.Strong
This is one finding among thousands. Every one is graded and traced to its source, so you can see what the evidence actually supports. Browse the research →